Travere Therapeutics, Inc.
0 products tracked · names used in filings: Travere Therapeutics, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
FILSPARI: PDUFA target action date (Focal segmental glomerulosclerosis (FSGS))
Travere Therapeutics, Inc. (TVTX); sparsentan; sNDA; status: set; "net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal…"; filed 2026-02-19 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.